Elgan Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2018-05-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.elganpharma.com
Clinical Trials
5
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:3
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 3
2 (40.0%)Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Phase 2
Not yet recruiting
- Conditions
- Intestinal Malabsorption
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05904626
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05670951
- Locations
- 🇮🇱
Laniado Hospital, Netanya, Israel
Safety and Efficacy Study in Infant With SBS
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT02865122
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
Phase 3
Terminated
- Conditions
- Premature Birth of NewbornIntestinal Malabsorption
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT02510560
- Locations
- 🇺🇸
Vidant Medical Center, Greenville, North Carolina, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Oral Formulation of Insulin for Preterm Infants
Phase 2
Terminated
- Conditions
- Premature Birth of Newborn
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT01093638
- Locations
- 🇮🇱
NICU, Laniado Hospital, Netanya, Israel
News
No news found